ProCE Banner Activity

RCC Treatment Choices: How We Are Applying Current Evidence and Guideline Recommendations in Clinical Practice

Clinical Thought
Drs Katy Beckermann, Naomi Haas, and Eric Jonasch provide key updates on the use of available regimens in renal cell carcinoma across the adjuvant, first-line, and second-line settings.

Released: August 01, 2022

Expiration: July 31, 2023

No longer available for credit.

Share

Faculty

Katy Beckermann

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

Naomi B. Haas

Naomi B. Haas, MD

Professor
Division of Hematology/Oncology
Director
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Eric Jonasch

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AVEO Pharmaceuticals, Inc.

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

Katy E. Beckermann, MD, PhD: consultant: Aravive, Aveo, Bristol Myers Squibb, Exelixis, Seagen; researcher: Bristol Myers Squibb.

Naomi B. Haas, MD

Professor
Division of Hematology/Oncology
Director
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Naomi B. Haas, MD: consultant: Aveo, Eisai, Merck, Roche Genentech.

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Eric Jonasch, MD: consultant: Aravive, Aveo, Calithera, DAVA, Eisai, Exelixis, Genentech, Ipsen, Merck, NiKang, Novartis, Takeda; researcher: Arrowhead, Merck, NiKang, Novartis.